MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathwayJianhui Li, Xiaoyu Yin|Journal of Experimental & Clinical Cancer Research|2019Cited by 45
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.Ye Guo, Jin Li, Weimin Ding et al.|Journal of Clinical Oncology|2023Cited by 11